Device Trial Radar · NCT07286357
A Data Collection Protocol to Evaluate the Real World Usage of the Orthofix AccelStim Device to Treat Fresh Metatarsal Fractures
Last checked: Nov 20, 2026Latest source record: Dec 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
May 30, 2025
Primary completion
Jun 30, 2026
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Orthofix Inc.Public (OFIX)
- Sponsor type
- Industry
- First posted
- Dec 16, 2025
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study examines the effect of using the AccelStim bone growth stimulator on subjects undergoing treatment for fresh metatarsal fractures.
Conditions
- Metatarsal Fracture
Interventions
AccelStim (LIPUS)Device
Subjects treated with LIPUS were directed to use the AccelStim device for 20 minutes per day, up to 6 months or until no longer needed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Healing StatusTime frame: 3, 6, and 12 month
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Northwestern
Evanston, Illinois
Endeavor Health
Mount Prospect, Illinois
Precision Orthopedics
Laurel, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.